Progress in Precision Medicine for GIST Patients
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
Clinical Trials Update – February 2022
In this summary, we continue highlighting recent clinical trials that are still recruiting in the U.S. which investigate potential treatments for GIST patients.
Clinical Trials Update – December 2021
December 2021 - In this summary, we have highlighted recent clinical trials that are still recruiting in the U.S. which investigate potential treatments for GIST patients.
What GISTers Need to Know About Clinical Trials
Dr. David Josephy and Jim Hughes discuss clinical trials for GISTers and what you need to know.
Blueprint Medicines Announces Publication in The Lancet Oncology
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
FDA Approves QINLOCK (ripretinib) by Deciphera for 4L GIST Patients
The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
Increasing the Quality and Efficiency of Clinical Trials
The mission of the Clinical Trials Transformation Initiative (CTTI) is to develop and drive the adoption of practices that will increase the quality and efficiency of clinical trials.
A ‘Clinical Trial of One’
October's LRG newsletter features artist Douglas Morgan, who found himself with a rare GIST mutation and no treatment options until an innovative oncologist and a compassionate gesture by a pharmaceutical company gave him a chance to receive a unique treatment.
LRG Webcast Series: Updates on the Temozolomide Trial
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.